Live Breaking News & Updates on Cerashield Endotracheal Tube
Stay updated with breaking news from Cerashield endotracheal tube. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Endotracheal Tube market revenues were estimated at US$ 2.2 Billion in 2021 and is anticipated to grow at a CAGR of 6.8% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 4.5 Billion.Due to an increase in surgical procedures,. ....
N8 Medical's CeraShield™ Endotracheal Tube Receives Health Canada Medical Device License sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
KINNEAR PHARMACEUTICALS ANNOUNCES FUNDING AGREEMENT WITH THE CYSTIC FIBROSIS FOUNDATION texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
iCrowdNewswire Jan 26, 2021 9:00 AM ET Support for preclinical testing for a novel broad spectrum inhaled anti-infective that rapidly eradicates microbial biofilms which are present in the lungs of Cystic Fibrosis patients DUBLIN,OHIO (26 January 2021) Kinnear Pharmaceuticals (Kinnear)announces an agreement with the Cystic Fibrosis Foundation on a staged Therapeutic Development Award (TDA) providing development funds for Kinnear’s lead compound, CSA-131. The staged award of up to $3 million, supported with matching funds from Kinnear, provides funding for preclinical research to enable the filing of an Investigational New Drug (IND) application with the FDA in 2022. “We are pleased and honored to announce this agreement with the Cystic Fibrosis Foundation to help progress CSA-131 as a novel therapeutic drug candidate for CF lung infections. Individuals living with CF are frequently burdened with life-threatening lung infections resulting from highly drug-res ....